Mov Disord Vol 34, Suppl 2 Archives - Page 69 of 217 - MDS Abstracts

2019 International Congress
A randomised rater-blinded study of motor consequences of inactivity in Parkinson’s disease revealing a new phenomenon: Stasis Induced Akinesia
M. Schumacher, S. Tisch (Sydney, Australia)
Objective: To evaluate experimentally the effects of prolonged sedentary inactivity on Parkinson’s disease (PD) motor function. Background: A frequently described but hitherto unreported symptom among…
2019 International Congress
Successful altruistic living kidney donation in a patient with Huntington’s disease
C. Cooper, S. Chen, B. Bernard, J. Goldman (Chicago, IL, USA)
Objective: To report a case of a Huntington’s Disease (HD) patient who underwent living kidney donation and examine the decision-making process and ethical considerations of…
2019 International Congress
Magnetic Resonance Spectroscopy Evaluation of Neuronal Integrity and Astrocytosis in a Phase 2 Study of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)
B. Leavitt, R. Reilmann, M. Gordon, K. Anderson, A. Feigin, S. Tabrizi, J. Stout, P. Piccini, B. Russell-Schulz, A. Mackay, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Vancouver, BC, Canada)
Objective: Evaluate the effect of laquinimod on putaminal and frontal white matter markers of neuronal integrity and astrocytosis using magnetic resonance spectroscopy (MRS) in patients…
2019 International Congress
Mobility Impairments in Huntington’s Disease due to Cognitive Dysfunction
M. Rakhimova, N. Yusupova (Tashkent, Uzbekistan)
Objective: This study examined the relationships of mobility, motor and cognitive function measures at baseline, and of mobility and cognitive measures over four years Background:…
2019 International Congress
Prolonged-release Melatonin for Sleep Disorders in Parkinson’s Disease: A Randomized trial
JH. Ahn, M. Kim, JK. Mun, J. Youn, S. Park, W. Jang, J. Park, E. Oh, JW. Cho, JS. Kim (Seoul, Republic of Korea)
Objective: To evaluate the efficacy of PRM in sleep disorders of patients with PD was investigated. Background: Sleep disorders are highly prevalent in patients with…
2019 International Congress
Enabling efficient use of digital health technologies to support Parkinson’s disease drug development through precompetitive collaboration
J. Cedarbaum, K. Taylor, D. Hill, R. Alexander, Y. Luo, R. Rubens, N. Zach, J. Cosman, A. Dowling, K. Fisher, L. Oliva, J. Hitchcock, M. Lawton, D. Conrado, K. Romero, M. Minchik, D. Meulien, B. Yang, M. Forman, L. Bataille, D. Dexter, J. Gallagher, M. Braxenthaler, M. Lindemann, B. Boroojerdi, G. Stebbins, B. Bloem, M. Hu, E. Dorsey, D. Stephenson (Cambridge, MA, USA)
Objective: To describe the Critical Path for Parkinson’s (CPP) consortium approach to advance the field of digital technologies in clinical drug development for Parkinson’s disease…
2019 International Congress
Dopamine receptor variants alter outcomes with levodopa in early-stage Parkinson’s disease
D. Fischer, P. Auinger, J. Goudreau, A. Cole-Strauss, K. Kieburtz, J. Elm, M. Hacker, P. Charles, J. Lipton, B. Pickut, C. Sortwell (Grand Rapids, MI, USA)
Objective: To examine if specific single nucleotide polymorphisms (SNPs) in the genes for dopamine receptors 2 and 3 (DRD2, DRD3) correlate with worse outcomes within specific…
2019 International Congress
Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product
R. Hauser, S. Isaacson, A. Mittur, A. Formella, R. Patni (Tampa, FL, USA)
Objective: To demonstrate the unique shape and pharmacokinetic (PK) profile of Gocovri® (amantadine) extended release (ER) capsules by using metrics pertinent to ER dosage forms.…
2019 International Congress
Changes in Supine Blood Pressure with Long Term Use of Droxidopa
S. Gorny, L. Hewitt, A. Lindsten, M. Karnik-Henry, S. Kymes, A. Favit (Deerfield, IL, USA)
Objective: To determine the long-term effects of droxidopa use on supine blood pressure (BP) in patients with neurogenic orthostatic hypotension (nOH). Background: nOH is a…
2019 International Congress
Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations
C. Liguori, M. Pierantozzi, R. Cerroni, NB. Mercuri, A. Stefani (Rome, Italy)
Objective: The aim of this clinical observation was to verify the sparing of levodopa in patients affected by Parkinson's disease who already started safinamide treatment for…